• Mineralys Therapeutics Chief Medical Officer David Malcom Rodman sold 417 shares of common stock on May 18 at USD 27.55.
• The sale followed the exercise of a stock option for 417 shares at USD 15.44 on the same day.
• He ended the transactions with 63,443 shares of common stock.
• Rodman also reported 4,167 stock options beneficially owned following the transaction, with an exercise price of USD 15.44.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001933414-26-000086), on May 19, 2026, and is solely responsible for the information contained therein.